Taklimat "Regulatory Updates" 2016

24 Februari 2016 (Rabu) 2.30 petang Dewan Anggerik, BPFK

> En. Tan Ann Ling Pengarah Regulatori Farmasi

Presentation Points

Policy Reminders
Policy Updates
Proposed New Policies & Future Plans
QUEST 3+ Updates

• Use of generic name as product name

- Pharmaceutical products (A & X) are not allowed to use generic name (International Proprietary Name, INN) as standalone for product name.
- Use of generic name as product name should be simultaneously with a name other than generic name (example: brand name) to enable differentiation between products and to avoid confusion among public.
- For example, product name Atenolol Table 50mg is not allowed, whereas <XYZ> Atenolol Tablet 50mg is allowed.

• Effective:

- 21 Dec 2015 (new registration)
- 1 Jan 2017 (existing products)

API Policy Reminder

- Regulatory control of API in registered pharmaceutical products containing scheduled poisons (all dosage forms).
 - Products with registrations that expire 1st January 2020 onwards.
 - The registration holder must submit documents with the required API information <u>at least 1 year</u> before the registration expires.
 - Implementation date of control of API for new applications:
 - Parenteral dosage form \rightarrow 1 July 2014
 - Oral dosage form → 1 July 2016
 - Dosage form other than parenteral and oral \rightarrow 1 July 2018
 - Bil (11) dlm BPFK/PPP/01/03 Jld 3

 Stability Studies (Zone IVb) for currently Registered Products for renewal - Reminder

- Extension ended 31 Disember 2015
- Required for all products renewal starting 1 Jan 2016
- Products that are not stable at 30⁰C need to be reformulated and the manufacturers must provide the new stability study data after the product has been reformulated.

- Requirement for full time registered pharmacist to head the production section of all pharmaceutical, radiopharmaceutical and veterinary product manufacturing premises registered with the DCA.
 - Pharmaceutical product manufacturers (Poison & OTC)
 - Effective: 1 January 2017
 - Veterinary product manufacturers (Schedule Poisons)
 - Effective 1 July 2020

- Bioequivalence (BE) Report Required
 - All scheduled Poisons formulated in Tablet/ Capsules formulated as effervescent, dispersible, orodispersible, sublingual, buccal, chewable
 - New Application: 1 July 2016
 - Existing : 1 July 2017
 - Circular: 23rd February 2015

- Product Owner
 - Full rights over products
 - Appointment of PRH etc
- Product Registration Holder (PRH)
 - Owns registration rights of product
 - Legally accountable for product
- Change of Holder Procedure
 - Both parties must agree
 - Otherwise product deregistered New application

- Medical device and pharmaceutical combination products.
 - All products under this category is classified according to primary mode/mechanism of action
 - SOP on registration process is being finalised and will be uploaded on web-site for comment
- Certain Products previously regulated as pharmaceuticals is currently regulated as medical devices:
 - Haemodialysis solutions, medicated plaster etc
 - Enforcement: Extended to July 2016
 - Allowed to be renewed as pharmaceuticals until this date
 - Future Plans: To be accreditated under ISO 13485

Biologics Product Registration

- All applications must comply with both requirements of Centre for Registration as well as Centre for Quality Control.
- Application will not be registered if the dossier does not meet the quality control requirements.
- Product Registration Holders (PRH) that cannot be contacted (including cosmetics) - Update
 - DCA has decided that the products of these PRHs will be cancelled instead of suspended after 6 weeks from first attempt.
 - Circular dated 17 December 2014 will be updated
 - New applications required if PRH still want to market products

- Registration of products containing ingredients from parts of controlled animals - Traditional Medicines
 - If the product formulation contains active ingredients of wild animals/controlled animals/plants origins, it is the responsibility of the PRH to obtain appropriate license/permit and comply to the follow acts:
 - Wildlife Conservation Act 2010 (Act 716)
 - > International Trade in Endangered Species Act 2008 (Act 686).
 - License/permit must be submitted during product registration process.

Implementation of fees for services provided by NPCB

- 1. Product Classification
- 2. Change of manufacturing site (Type 1)
- 3. Local BE Centre Inspection
- 4. GLP inspection on non-clinical study facility in Malaysia.
- 5. Manufacturing Facility Floor Plan Evaluation
- 6. Indication and Declaration Certificate
- 7. Vaccine Lot Release/Cold Chain Inspection

Effective 1 January 2016

- Implementation of fees for services provided by NPCB
 - Product Variation
 - Additional Indication
 - Effective 1 July 2016

Importation of unregistered vaccine

- Mandatory document: Release letter from NRA of country of origin, packing list and AWB
- Cold chain inspection shall be conducted within 2 working days after product arrival at the warehouse
- Cold Chain Inspection Fee
- No Lot Release Fee as NPCB will not do Lot Release for Unregistered Vaccines

- Fees for BE & GLP inspections
 - Maximum : RM10,000/inspection
- New Timeline for Services:
 - Product Classification
 - FDI: 7 working days
 - MDDCI : 14 working days
 - Indication and Declaration certificate: 14 working days
- Other services (At the moment)
 - No change in timeline
 - No change in fees

Proposal Charges for Services

BIL	PERKHIDMATAN / AKTIVITI	YURAN YANG D	YURAN YANG DICADANGKAN		
1.	Pemprosesan Pengkelasan Produk	gkelasan Produk RM 3			
	Pemprosesan Permohonan Variasi Produk dan	Penilaian penuh	Penilaian ringkas		
	Tambahan Indikasi	(A, X, H)	(N,T, H)		
	Minor Variation prior approval (MiV-PA)	RM150 setiap jenis	RM50 setiap jenis		
2.	$\frac{1}{1} \frac{1}{1} \frac{1}$	permohonan	permohonan*		
	Major Variation (MaV)	RM300 setiap jenis	RM100 setiap jenis		
	(v_{1a}, v_{1a})	permohonan	permohonan		
	Tambahan indikasi	RM1000	Tidak berkenaan		
3.	Pemprosesan Permohonan Pertukaran Tapak	Farmaseutikal	Tradisional		
	Pengilang Jenis I	(A, X, N, H)	(T)		
		RM1000 setiap produk	RM100 setiap produk		
	Pemprosesan dan Pemeriksaan Pusat Kajian Bioekuivalens (BE) Tempatan				
	Yuran Pemprosesan Permohonan**	R	RM1,000		
	Penilaian Dokumentasi***	R	RM1,000		
4.	Pemeriksaan Penuh (Klinikal, Bioanalitika	al dan BM1.000/por	n RM1,000/pemeriksa/hari bekerja		
	Method Validation)	KW1,0007 pc1			
	Pemeriksaan Tambahan Tapak Klinikal / Bioana	alitikal RM1,000/per	RM1,000/pemeriksa/hari bekerja		
	Pemeriksaan Verifikasi	RM1,000/per	RM1,000/pemeriksa/hari bekerja		
	Pemeriksaan Triggered [#]	RM1,000/per	RM1,000/pemeriksa/hari bekerja		

Proposal Charges for Services

BIL	PERKHIDMATAN / AKTIVITI	YURAN YANG DICADANGKAN	
	Pemeriksaan Amalan Makmal Baik (Good Labroratory Practice, GLP) ke atas Fasiliti		
	Kajian Bukan Klinikal di Malaysia		
	Permohonan	RM 2000	
	Penilaian dokumentasi	RM 2000	
5.	Pra-pemeriksaan	RM 2000/hari/inspektor	
э.	Pemeriksaan	RM 2000/hari/inspektor	
	Verifikasi	RM 2000/hari/inspektor	
	Surveilan	RM 2000/hari/inspektor	
	Yuran pakar teknikal	RM 2000/hari/inspektor	
	Sijil Tahunan	RM 2000	

Proposal Charges for Services

	Aktiviti Penilaian Susun Atur Premis	Pelan	Permohonan Pelan B	aru	Permohonan Pindaan Pelan
6.	Semua jenis pelan su premis pengilang produ		RM1,000		RM500
7.	Pemprosesan Permohonan Sijil Indikasi dan Sijil Deklarasi		RM50 / setia	p sijil yar	ng dikeluarkan
	Pemprosesan Aktiviti Vaccine Lot Release				
	Jenis Vaksin	Pemeriksaan Rangkaian Sejuk dan Penilaian Lot Summary Protocol			iksaan Rangkaian Sejuk bagi nmary Protocol yang pernah dinilai
	Semenanjung Malaysia				
8.	Monovalent		RM300 / lot vaksin	RM200 / lot vaksin	
0.	Polyvalent		RM500 / lot vaksin		
	Combination]	RM1000 / lot vaksin		
	Sabah dan Sarawak				
	Monovalent		RM600 / lot vaksin	RM500 / lot vaksin	
	Polyvalent		RM800 / lot vaksin		
	Combination]	RM1300 / lot vaksin		
		on de	to, to be approving	ad	

Implementation date: to be announced

Latest Foreign GMP/BE Inspection Fee

Description	Amount	Payment dateline
Processing fee	RM 5,000.00	Together with application submission
Inspection cost contribution	Subject to estimation of actual expenses	BeforeTrust Fund Meeting -April and October
Inspection fee	RM 20,000.00	1 week before inspection

Effective 1 January 2016

Product Renewal

- Product registration holders cannot renew the registration if the registration has expired/cancelled
- > No appeal will be allowed
 - Reminder: Renewal to be submitted 6 months before expiry.
- A new application for registration has to be submitted if PRH wishes to continue to market the product.

- Menthol and Camphor as Active Ingredient in Traditional Products
 - Status for existing products remain the same while products submitted for new registration cannot contain menthol and camphor as active ingredient.
- Requirement for Certificate of Analysis (CoA) for finished product during new product registration application for TMHS with general claims
 - CoA for finished product is required as follows:
 - Import product : 2 batches
 - Local product : 1 batch

Adulterated products manufactured overseas

- Registered Products/Notified Cosmetics from manufacturer concerned will be cancelled/denotified.
- New applications for products from manufacturer concerned will not be allowed.
- List of Cosmetic Manufacturers in Malaysia that Conforms to the ASEAN Guideline For Cosmetic Good Manufacturing Practice.
 - List has been uploaded to the website starting 4 January 2016

- Directive on Requirement of Overseas GMP Inspection for the Purpose of Registration/ Renewal of Pharmaceutical Products with Drug Control Authority
 - Approved by DCA in January 2016 Meeting
 - NPCB will perform GMP Inspections on facilities in non- PICS countries whether or not these facilities have been inspected by NDRAs of other PICS countries
 - New Registration: 1 July 2016
 - Existing Products: Upon renewal starting **1 January 2017**
 - SOP will be prepared by Centre for Compliance & Licensing
 - Conditional renewal if inspections cannot be carried out before expiry.

Plasma Products Lot Release

- Plasma products lot release activity is implemented via evaluation of Lot Summary Protocol, physical and cold chain inspection to ensure safety, quality and efficacy.
 - Pilot Project: 1 January 2016
 - Full Implementation: 1 July 2016
- Fees for Lot Release & Cold Chain Inspections
 - Same as for Vaccines (Monovalent)
 - Proposed Implementation Date: 1 July 2016

- New requirement for Option 2 validation process in new pharmaceutical product and variation application:
 - According to the ASEAN Guideline on Submission of Manufacturing Process Validation Data for Drug Registration, there are new requirements for companies who select Option 2 in submission of process validation report:
 - Pharmaceutical Product Development Report
 - Validation data for 1 pilot batch along with validation scheme for commercial batch
 - Letter of commitment to ensure that company will only market the product after the satisfactory completion of process validation for 3 consecutive commercial batches.

New requirement for Option 2 validation process in new pharmaceutical product and variation application:

 Option 2 is not allowed for biologic/biotechnological products, products that are manufactured via a non-standard manufacturing process, such as non-standard sterilization method, aseptic products and other specialised products (example: products in a modified release dosage form).

Effective 1 March 2016

List of Panel Laboratories for THMS Products

- List to be upload on Website soon
 - Listed Laboratories with list of approved tests
 - Validity: 3 years
 - Dynamic updated whenever new laboratories approved
- Objective;
 - Applicants have option to send to NPCB or Listed Laboratory
 - Testing facilities available to TMHS PRH
 - Registration
 - Product Release for Sale: Requirement for every batch to be tested
- Implementation Date: To be determined

Biologics – Second/Third Source

- New category of 2nd/3rd source application Conditions:
 - The proposed facility is approved for manufacturing activities for the same company/sponsor
 - No change in specification of drug substance
 - No change in the composition, manufacturing process and drug product specifications
 - No change in the container/closure system
 - The same validated manufacturing process is used
 - The newly introduced product is in the same family of product(s) or therapeutic classification as the one of those already approved at the site and uses the same filling process/equipment

• Biologics – Second Source

- If ALL conditions are met, an abbreviated product dossier can be submitted (e.g. proposed process validation protocol, 6 months stability data from the new source)
 - Processing time: **60** working days
- If one/more of the conditions are NOT met, the product dossier requirements as per new product registration (e.g. process validation, real time stability data) apply
 - Processing time: **245** working days

• Cell and Gene Therapy Products (CGTPs)

- Guidelines and Framework approved by DCA in January 2016
- Guidelines to be uploaded on BPFK Website
- Transition period: 5 years (2016-2020)
 - Voluntary Registration only registered CGTPs can be used for therapy
 - Status Quo only for research purposes, with CTIL/CTX from BPFK
- Integrated Approach
 - Treatment facilities under the purview of Medical Practice Division, MOH
 - Private Healthcare Facilities and Services Act

Traditional medicines

- Allow indication based on philosophy of use
- For Compendia Formulation Only
 - Indian, Chinese etc
- New category of products
 - Natural Products
 - General, Medium & High Claims
 - Animal / Herbal / Mineral origin

• GST – Zero Rated

- Required suffix 'Z' in Registration Number
 - All products (A & X)
 - Option: Stick-on Label (Zero-rated)
 - To discuss with MOF
 - Implementation Date: 1 July 2016
- Required to be listed and gazetted by Customs
 - List updated every 3 months
 - Newly registered products (all Group 'A' products, etc.)
 - Registered products with updates of registration code (C, R)
 - New items to be added in the National Essential Medicines List (NEML).

• GST – Zero Rated

- Unregistered Product can be included if meet criteria — NEML/Scheduled Poison
- All drug products which has been reclassified as Medical Device will still be listed as 'zero-rated supply' for GST:
 - enforcement date of medical device product registration (1st July 2016) or
 - new gazettement by the federal government.
- Proposal: To develop National Essential Medical Device List

Products Registered but not Marketed

- Misleading
 - Old Registration Number but no history of use in Malaysia
 - Many brands registered but only very few are aavailable
- Access Issue
 - Government Procurement
 - Many products registered but not available
- Proposal: If product not marketed within one registration cycle, product will deregistered??

- Wholesale Licence Good Distribution Practice (GDP)
 - Issued in accordance to facilities available
 - Normal Products
 - Cold Chain Products Logistics, Storage etc

• API Manufacturers

- Implementation of Manufacturer's Licensing Requirements
 - PIC/S GMP
 - Scheduled Poison & OTC

Cosmetic Manufacturers

- Certificate of GMP compliance
 - ASEAN Cosmetic GMP Guidelines

- Appeal Process Upon Rejection of Registration Applications
 - Appeal only for rejection based on Safety, Efficacy and Quality
 - Appeal not allowed for rejection based on:
 - Incompleted documentation/information/data
 - No reply from applicants
 - Exceeded number of correspondence allowed
 - Exceeded time allowed for correspondence
 - Failed Quality Control Analysis
 - GMP/BE issues
 - Applicant allowed to submit New Application
 - Complete data/documentation required

• TPPA – 3 Main Obligations

- Data Exclusivity
 - New Directive to be issued in line with TPPA obligations
- Patent Linkage
 - Notification system
- Patent Term Adjustment
 - To comply

Registration Cycle

- Current : 5 years
- Proposal to review

• Halal logo on Label

- Suggestion to allow on prescription products.
- Public Engagement with all stakeholders
- Voluntary

- GLP Requirement For Product Registration
 - All non clinical safety studies submitted for registration of products involving New Chemical Entity (NCE), biologics, biotechnology and herbal with high therapeutics claim must be conducted under GLP.
 - A **Final Report must be provided** for each of the non clinical safety studies conducted
 - Proposed Implementation Date : 1 January 2017

• Foreign BE Inspection Report

- BE inspection report from USFDA can be accepted for review only for BE centres operate in US and Canada.
- BE inspection report from European Medicines Agency (EMA) and selected EU drug regulatory agencies can be accepted for review only for BE centres operate in Europe and Canada.
- Acceptance of the BE centres based on the inspection reports are depending on the scope and evaluation of the inspection reports.
- Proposed Implementation Date: 1 January 2017

- Proposed Fees for New/Existing Services
 - Product Application Screening
 - Fast Track Application
 - Must fulfill fast-track criteria
 - Review Present Registration Processing Fee
 - Review Renewal Fee
 - Other services

 Proposed Revised Processing fees for CTIL, CTX and Variation Application

Type of application	Current fee	Proposed revised fee
CTIL	RM 500 per product	RM 3,000 per product
СТХ	Free of charge	RM 1,000 per product
Variation	Free of charge	RM 500 per application


NEW FEATURES IN QUEST3+


Features	Details
Payment mode	 2 types of online payment : i) Internet banking via Financial Process Exchange (FPX) ii) Credit Card via MasterCard Internet Gateway Service (MiGS)
Security Token	Digital signature authentication provided by MSC Trustgate Sdn Bhd Applicant still can use the existing Digicert USB Token until its expiry date HOWEVER it is Mandatory to renew using new USB token by MSC Trustgate
Others	Limited number of correspondences Milestones for Correspondences/Replies

NEW FEATURES IN QUEST3+

Modules	New Features
Product Registration	 Screening process in the evaluation work flow Information for API based on active substance and manufacturer
Licensing	Application for Manufacturing, Import and Wholesale Licence through online system
Quality Control	Screening process in the protocol & validation evaluation work flow
Cosmetic	 Additional information in attachment format for :- 1. Product Label 2. Letter of Authorisation include Letter of Contract Manufacturing Appointment and Acceptance

QUEST MORATORIUM





QUEST 3+ Updates

- Discussion session with industry in March/April
 - Mechanism for Moratorium
 - New Applications
 - Variations
 - Outstanding Applications
 - Milestones for correspondence
 - Data Migration
 - Industry Concerns
 - Training Requirements

